Production (Stage)
SAB Biotherapeutics, Inc.
SABS
$1.93
$0.126.63%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | -70.83% | -63.30% | 1,153.37% | 380.11% | 237.34% |
| Total Receivables | -88.92% | -- | -- | -38.23% | -74.68% |
| Inventory | -- | -- | -- | -- | -- |
| Prepaid Expenses | 26.80% | 27.16% | 190.42% | 133.92% | 123.44% |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
| Other Current Assets | -- | -- | -- | -- | -- |
| Total Current Assets | -65.29% | -59.61% | 940.29% | 339.48% | 212.34% |
|
|
|||||
| Total Current Assets | -65.29% | -59.61% | 940.29% | 339.48% | 212.34% |
| Net Property, Plant & Equipment | -5.55% | -19.30% | -16.47% | -16.20% | -16.82% |
| Long-term Investments | -- | -- | -- | -- | -- |
| Goodwill | -- | -- | -- | -- | -- |
| Total Other Intangibles | -- | -- | -- | -- | -- |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
| Total Other Assets | -18.81% | 37.66% | 38.58% | 20.21% | 27.65% |
| Total Assets | -46.59% | -47.35% | 89.85% | 74.63% | 67.26% |
|
|
|||||
| Total Accounts Payable | 103.27% | 79.16% | 19.74% | -16.56% | -14.19% |
| Total Accrued Expenses | 17.03% | -18.22% | 29.80% | -14.73% | -36.79% |
| Short-term Debt | -- | -- | -- | -- | -- |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Current | -28.80% | -56.19% | -56.27% | 54.38% | 38.13% |
| Total Finance Division Other Current Liabilities | -- | -- | -92.95% | -96.04% | -87.15% |
| Total Other Current Liabilities | -- | -- | -92.95% | -96.04% | -87.15% |
| Total Current Liabilities | 16.24% | -26.21% | -4.29% | -31.41% | -39.23% |
|
|
|||||
| Total Current Liabilities | 16.24% | -26.21% | -4.29% | -31.41% | -39.23% |
| Long-Term Debt | -- | -- | -- | -- | -- |
| Short-term Debt | -- | -- | -- | -- | -- |
| Capital Leases | 44.88% | -4.86% | 15.73% | 15.47% | 3.00% |
| Finance Division Debt Non Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Liabilities | -78.54% | -45.74% | 878.88% | 586.19% | 2,546.24% |
| Total Liabilities | -9.90% | -31.59% | 29.16% | 0.29% | 1.53% |
|
|
|||||
| Common Stock & APIC | 1.90% | 1.92% | 76.33% | 76.43% | 80.27% |
| Retained Earnings | -36.05% | -37.87% | -67.80% | -64.92% | -72.19% |
| Treasury Stock & Other | -0.86% | -2.95% | 0.94% | -0.57% | -1.15% |
| Total Common Equity | -59.47% | -54.68% | 141.89% | 133.91% | 116.46% |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Convertible | -- | -- | -- | -- | -- |
| Preferred Stock, Others | -- | -- | -- | -- | -- |
| Total Preferred Equity | -- | -- | -- | -- | -- |
|
|
|||||
| Total Common Equity | -59.47% | -54.68% | 141.89% | 133.91% | 116.46% |
| Total Preferred Equity | -- | -- | -- | -- | -- |
| Total Minority Interest | -- | -- | -- | -- | -- |
| Total Equity | -59.47% | -54.68% | 141.89% | 133.91% | 116.46% |
|
|
|||||